This action follows a consumer report of fungal contamination in a sealed single-use vial. While no adverse events have been ...

As 2024 comes to a close, we here at Ophthalmology Times and the greater Eye Care Network would like to thank you–the reader.

Deepinder Dhaliwal, MD, LAc, discusses longterm outcomes of Descemet Stripping Only (DSO) for Fuchs dystrophy at NYU's ...

The NYU Grossman School of Medicine launches a Journal Club series with Ophthalmology Times, featuring expert faculty ...

A Helsinki University Hospital study found diabetes, glycemic control, or insulin therapy did not significantly affect ...

Alon Kahana, MD, PhD, discusses the role of interleukin-6 in thyroid eye disease and the potential of tourmaline Bio's IL-6 ...

Deepinder Dhaliwal, MD, LAc, explores advancements in managing Fuchs endothelial corneal dystrophy, highlighting Descemet ...

Glaukos submitted an NDA for Epioxa, a novel corneal cross-linking therapy for keratoconus, to the US FDA. Epioxa's Phase 3 ...

According to Iridex Corp., the study confirms MicroPulse TLT's sustained safety and efficacy in managing glaucoma, reducing ...

QUASAR is a global, double-masked, active-controlled phase 3 trial evaluating the efficacy and safety of EYLEA HD, compared ...

The company is advancing its Phase I/II trial and exploring accelerated approval pathways in the US and Europe.

THRIVE-2 met all primary and secondary endpoints at the 15-week primary analysis timepoint after 5 infusions of veligrotug.